Immatics N.V. (IMTX) stock
IMTXNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.39−0.13 (-1.99%)
Close on Nov 13, 2026Market cap $856.72MP/E –Yield –
Immatics EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
For fiscal 2025 it was -1.61 EUR, down 1250.0% from the year before. The highest annual figure on record is 0.40 EUR in fiscal 2022.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -1.61 EUR | -1250.0% |
| FY2024 | Dec 31, 2024 | 0.14 EUR | – |
| FY2023 | Dec 31, 2023 | -1.18 EUR | -395.0% |
| FY2022 | Dec 31, 2022 | 0.40 EUR | – |
| FY2021 | Dec 31, 2021 | -1.48 EUR | – |
| FY2020 | Dec 31, 2020 | -4.40 EUR | – |
| FY2019 | Dec 31, 2019 | -0.95 EUR | – |
| FY2018 | Dec 31, 2018 | -0.95 EUR | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -0.46 EUR | – |
| Q2 FY2025 | Jun 30, 2025 | -0.58 EUR | – |
| Q3 FY2024 | Sep 30, 2024 | -0.08 EUR | – |
| Q2 FY2024 | Jun 30, 2024 | -0.17 EUR | – |
| Q1 FY2024 | Mar 31, 2024 | -0.03 EUR | – |
| Q2 FY2023 | Jun 30, 2023 | -0.32 EUR | – |
| Q2 FY2022 | Jun 30, 2022 | -0.22 EUR | – |
| Q2 FY2021 | Jun 30, 2021 | -0.42 EUR | – |
| Q2 FY2020 | Jun 30, 2020 | -0.64 EUR | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?